Helius Medical Technologies, Inc.

Equities

HSDT

US42328V8019

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-16 pm EDT			5-day change	1st Jan Change
1.52 ^USD	-3.18%		-10.59%	-81.09%

May. 13	Transcript : Helius Medical Technologies, Inc., Q1 2024 Earnings Call, May 13, 2024
May. 13	Earnings Flash (HSDT) HELIUS MEDICAL TECHNOLOGIES Posts Q1 Revenue $135,000	MT

Helius Medical Technologies, Inc. Announces Resignation of Huaizheng Peng from the Board

May 07, 2020 at 04:51 pm EDT

Helius Medical Technologies, Inc. announced that the Dr. Huaizheng Peng notified the Board of Directors of the Company that he resigned from the Board, effective May 1, 2020. Dr. Peng’s did not resign from the Board due to any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.

Latest news about Helius Medical Technologies, Inc.

Transcript : Helius Medical Technologies, Inc., Q1 2024 Earnings Call, May 13, 2024	May. 13
Earnings Flash (HSDT) HELIUS MEDICAL TECHNOLOGIES Posts Q1 Revenue $135,000	May. 13	MT
Earnings Flash (HSDT) HELIUS MEDICAL TECHNOLOGIES Posts Q1 Revenue $135,000, vs. Street Est of $0.1M	May. 13	MT
Exchange-Traded Funds Lower, Equity Futures Mixed Pre-Bell Tuesday as Traders Assess Earnings	May. 07	MT
Top Premarket Decliners	May. 07	MT
Helius Medical Technologies Prices $6.4 Million Public Offering	May. 07	MT
Top Premarket Gainers	May. 03	MT
Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center	Apr. 24	CI
Top Premarket Gainers	Apr. 03	MT
Helius Medical Technologies, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Transcript : Helius Medical Technologies, Inc., Q4 2023 Earnings Call, Mar 28, 2024	Mar. 28
Helius Medical Technologies, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 28	CI
Earnings Flash (HSDT) HELIUS MEDICAL TECHNOLOGIES Reports Q4 Revenue $134,000	Mar. 28	MT
Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke	Mar. 12	CI
Helius Medical Technologies, Inc. Secures HCPCS Codes for Portable Neuromodulation Stimulator (PoNS®) Mouthpiece and Controller	Mar. 04	CI
Traders Await Fresh Cues After Powell's Rate-Cut Commentary, Stifling US Equity Futures Pre-Bell	Feb. 06	MT
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Tuesday as Earnings Flow Intensifies	Feb. 06	MT
Top Premarket Gainers	Feb. 06	MT
Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients	Feb. 06	CI
Helius Medical Technologies, Inc. Announces Further Expansion of Stroke Clinical Program with the Addition of Brooks Rehabilitation Hospital	Jan. 11	CI
Earnings Flash (HSDT) HELIUS MEDICAL TECHNOLOGIES Reports Q3 Revenue $143,000	Nov. 09	MT
Earnings Flash (HSDT) HELIUS MEDICAL TECHNOLOGIES Reports Q3 Revenue $143,000	Nov. 09	MT
Helius Medical Technologies, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Transcript : Helius Medical Technologies, Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Helius Medical Technologies, Inc. Announces Impairment Charges for the Three Months Ended September 30 2023	Nov. 09	CI

Chart Helius Medical Technologies, Inc.

Duration

Period

More charts

Company Profile

Helius Medical Technologies, Inc. is a neurotech company in the medical device field. It is focused on neurologic deficits using orally applied technology platform that amplifies the brainâs ability to engage physiologic compensatory mechanisms enhancing the lives of people dealing with neurologic diseases. It develops, licenses, or acquires non-implantable technologies targeted at reducing symptoms of neurological disease or trauma. Its product Portable Neuromodulation Stimulator (PoNS) is a non-implantable medical device, inclusive of a controller and mouthpiece, which delivers mild electrical stimulation to the surface of the tongue to provide treatment of gait deficit and chronic balance deficit. PoNS Therapy is integral to the overall PoNS solution and is the physical therapy applied by patients during use of the PoNS neuromodulation stimulator. PoNS is used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-08-07 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Helius Medical Technologies, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

1.52 USD

Average target price

5.7 USD

Spread / Average Target

+275.00%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
HELIUS MEDICAL TECHNOLOGIES, INC.	-81.09%	4.09M
THERMO FISHER SCIENTIFIC	+12.50%	228B
DANAHER CORPORATION	+14.52%	196B
INTUITIVE SURGICAL, INC.	+17.51%	141B
BOSTON SCIENTIFIC CORPORATION	+28.96%	110B
SIEMENS HEALTHINEERS AG	+1.22%	65.88B
EDWARDS LIFESCIENCES CORPORATION	+18.16%	54.3B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	+7.63%	52.39B
AGILENT TECHNOLOGIES, INC.	+10.95%	45.22B
GE HEALTHCARE TECHNOLOGIES INC.	+5.10%	37.12B

Other Advanced Medical Equipment & Technology